Novel Oral Agent Proves Mettle in Obstructive Hypertrophic Cardiomyopathy

By News Health
7 hours Ago

(MedPage Today) — MADRID — The novel oral cardiac myosin inhibitor aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy (HCM) better than standard beta-blocker treatment, the MAPLE-HCM randomized trial…

Source link : https://www.medpagetoday.com/meetingcoverage/esc/117221

Author :

Publish date : 2025-08-30 07:18:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Killing of UnitedHealthcare CEO Has Inspired Followers, Prosecutors Say

High-Dose Flu Shot May Cut Some Hospitalizations in Older Adults

'Slimming jabs have changed the way we do things'

State Laws on Unilateral Decisions for Life Support Are All Over the Map

Getting a COVID Shot Just Became Much More Difficult. Here's Why.

'Weekend Warriors' See Lower Gout Risk, Similar to Gym Rats